Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 62

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 62
---
2025, (iv) 441,452 NLS Common Shares issuable upon conversion of Preferred Participation Certificates within 60 days of March 28, 2025, and (v) 5,621,494 NLS Common Shares issuable upon exercise of pre -fundedwarrants exercisable within 60 days of March 28, 2025, subject to a beneficial ownership limitation of 9.99%. The warrants are subject to a beneficial ownership limitation of 9.99%, which such limitation restricts Alpha Capital Anstalt from exercising that portion of the warrants that would result in Alpha Capital Anstalt and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. As a result, the number of NLS Common Shares reflected in the table owned by Alpha Capital Anstalt includes (a) any outstanding NLS Common Shares held by such shareholder, and (b) if any, the number of preferred shares and warrants convertible into NLS Common Shares that the holder has the right to acquire within 60 days of March 28, 2025 without such holder or any of such holder’s affiliates beneficially owning more than the beneficial ownership limitation of 9.99%. The address for Alpha Capital Anstalt is Lettstrasse 32, Vaduz 9490, Liechtenstein. Nicola Feuerstein, a Director of Alpha Capital Anstalt, holds voting and dispositive power over the securities held by Alpha Capital Anstalt. At the Closing, 96,649 RSUs issued by Kadimastem are expected to be exchanged for 270,989 RSUs of the combined company, and 175,600 Kadimastem options to purchase Kadimastem Ordinary Shares are expected to be exchanged for 492,357 options to purchase NLS Common Shares of the combined company. Q.What is the anticipated ownership of options, warrants and other outstanding equity awards that are anticipated to remain outstanding following the completion of the Merger? As of March 28, 2025, the expected total amount of RSUs of Kadimastem that will be exchanged for RSUs of NLS is 96,649 RSUs of Kadimastem, which will equal to 270,989 RSUs of NLS at the Effective Time. All such RSUs have been and shall continue to be owned by current and past officers and employees of Kadimastem, and represent approximately 1.11% of the estimated